2023 CCA Summit Conference Correspondent

Targeted inhibition of specific drivers in the tumor immune microenvironment in genetically defined cholangiocarcinoma subtypes may represent a rational approach for therapeutic intervention.

Emerging biomarkers based on molecular features of biliary tract cancers may be useful to predict treatment response and further guide treatment modifications.

Positron emission tomography/magnetic resonance imaging have a role in cholangiocarcinoma when compared with conventional computed tomography or positron emission tomography alone.

HER2-targeted therapies show promising antitumor activity and manageable safety profile in biliary tract cancers.

A long-term survival benefit with radiation therapy in conjunction with chemotherapy or immunotherapy may be feasible in some patients with unresected intrahepatic cholangiocarcinomas.

Although surgical resection has curative potential in intrahepatic cholangiocarcinoma, duration of long-term cure is low due to a high rate of recurrences, which may require locoregional and systemic therapies for disease management.

Current evidence supports the use of radioembolization in intrahepatic cholangiocarcinoma based on data showing that the addition of locoregional therapy prolongs survival and can downstage select patients to curative resection.

Liver-directed therapies have shown promise for first-line treatment of intrahepatic cholangiocarcinoma; however, it requires careful patient selection and institutional experience.

Pashtoon Kasi, MD, MS, discussed the use of liquid biopsy molecular profiling to identify actionable alterations and provide opportunities for precision medicine in patients with advanced cancers including cholangiocarcinoma.